Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Fountzilas

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Pharmaceutics|September 23, 2022
Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled TrialsKanak Parmar, Sai Subramanyam, Kristopher Attwood, et al.
Liver Cancer|October 21, 2020
Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness AnalysisChristopher Sherrow, Kristopher Attwood, Kehua Zhou, et al.
American Journal of Cancer Research|November 12, 2021
Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapyFengzhi Li, Christos Fountzilas, Igor Puzanov, et al.
Cancer|October 10, 2018
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignanciesChristos Fountzilas, Milind Javle, Wei Tan, et al.
Journal of Gastrointestinal Oncology|March 11, 2017
Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experienceChristos Fountzilas, Katherine Chang, Brian Hernandez, et al.
Journal of Surgical Oncology|August 19, 2024
Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinomaBrendan L Hagerty, Fatemeh Fekrmandi, Tyce Schneider, et al.
Targeted Oncology|December 6, 2019
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaSarbajit Mukherjee, Christos Fountzilas, Patrick M Boland, et al.
Nutrients|January 21, 2023
Sugar Sweetened and Artificially Sweetened Beverage Consumption and Pancreatic Cancer: A Retrospective StudyEvan W Davis, Susan E McCann, Janine M Joseph, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2024
Models using comprehensive, lesion-level, longitudinal [<sup>68</sup>Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [<sup>177</sup>Lu]Lu-DOTA-TATEVictor Santoro-Fernandes, Brayden Schott, Ali Deatsch, et al.
Familial Cancer|May 26, 2025
Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variantRiya Patel, Christos Fountzilas, Michael Horowitz, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Pharmaceutics|September 23, 2022
Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled TrialsKanak Parmar, Sai Subramanyam, Kristopher Attwood, et al.
Liver Cancer|October 21, 2020
Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness AnalysisChristopher Sherrow, Kristopher Attwood, Kehua Zhou, et al.
American Journal of Cancer Research|November 12, 2021
Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapyFengzhi Li, Christos Fountzilas, Igor Puzanov, et al.
Cancer|October 10, 2018
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignanciesChristos Fountzilas, Milind Javle, Wei Tan, et al.
Journal of Gastrointestinal Oncology|March 11, 2017
Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experienceChristos Fountzilas, Katherine Chang, Brian Hernandez, et al.
Journal of Surgical Oncology|August 19, 2024
Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinomaBrendan L Hagerty, Fatemeh Fekrmandi, Tyce Schneider, et al.
Targeted Oncology|December 6, 2019
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaSarbajit Mukherjee, Christos Fountzilas, Patrick M Boland, et al.
Nutrients|January 21, 2023
Sugar Sweetened and Artificially Sweetened Beverage Consumption and Pancreatic Cancer: A Retrospective StudyEvan W Davis, Susan E McCann, Janine M Joseph, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2024
Models using comprehensive, lesion-level, longitudinal [<sup>68</sup>Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [<sup>177</sup>Lu]Lu-DOTA-TATEVictor Santoro-Fernandes, Brayden Schott, Ali Deatsch, et al.
Familial Cancer|May 26, 2025
Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variantRiya Patel, Christos Fountzilas, Michael Horowitz, et al.
Pageof 8